Please Wait.....
Report
Pharmaceutical Drug Delivery Market By Route of Administration (Oral drug delivery, Nasal drug delivery, Ocular drug delivery, Topical drug delivery, Other drug delivery), By Application (Cancer, Diabetes, Cardiovascular Diseases, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-06-01 I 236 Pages I Allied Market Research
The pharmaceutical drug delivery market was valued for $1,498.72 billion in 2022 and is estimated to reach $2,307.27billion by 2032, exhibiting a CAGR of 4.4% from 2023 to 2032. Pharmaceutical drug delivery is defined as a process of administering medications or therapeutic substances to patients toachieve the desired therapeutic effect. It involves designing and development of various methods, systems, and technologiesthat enable safe and effective delivery of drugs to specific target sites within the body. Drug delivery systems aredeveloped to maximize the effectiveness of medications, reduce the potential adverse effects, enhance bioavailability, andimprove patient compliance. The common drug delivery methods are oral delivery, injectable delivery, transdermal delivery,topical delivery, targeted delivery, and others. The pharmaceutical drug delivery market growth is driven by an increase inthe number of people suffering from chronic diseases, rise in prevalence of geriatric population, and advancement in R&Dactivities in pharmaceutical industry.
Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow diseaseprogression, or maintain quality of life. This has increased the demand for effective drug delivery systems, therebydriving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in4 adults with diabetes live in low and middle-income countries and approximately 206 million people were diagnosed withdiabetes in western pacific.
For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro totreat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin deliverysystems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such ascardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand foreffective drug delivery.
For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food andDrug Administration (FDA) approval for LEQEMBI to treat Alzheimer's disease. LEQEMBI is a monoclonal antibody directedintravenous drug delivery medication that effectively treats Alzheimer's disease. Thus, development of new targeted drugdelivery and controlled release formulation further contribute toward the market growth. However, stringent regulatoryrequirements can increase the time, cost, and complexity of new drug delivery technologies and restrain market growth.Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.
On the other hand, an increase in demand for advanced drug delivery systems is expected to create lucrative opportunitiesfor market growth during the forecast period. This is attributed to the increase in prevalence of chronic diseases,enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drugdelivery systems.
The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. Onthe basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drugdelivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer,diabetes, cardiovascular diseases, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK,Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific),and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global pharmaceutical drug delivery market are Bayer AG, Cipla Ltd, F. Hoffmann-LaRoche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Keyplayers operating in the market have adopted product launch and product approval as their key strategies to expand theirmarket share and product portfolio.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Route of Administration
- Topical drug delivery
- Other drug delivery
- Oral drug delivery
- Nasal drug delivery
- Ocular drug delivery
By Application
- Cancer
- Diabetes
- Cardiovascular Diseases
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Amgen Inc.
- Bayer AG
- Cipla Ltd
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of various chronic diseases
3.4.1.2. Technological advancement in drug delivery systems
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery
3.4.3. Opportunities
3.4.3.1. Increase in demand for advanced delivery systems
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral drug delivery
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Nasal drug delivery
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Ocular drug delivery
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Topical drug delivery
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Other drug delivery
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Diabetes
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Cardiovascular Diseases
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Route of Administration
6.2.3. Market size and forecast, by Application
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Route of Administration
6.2.4.1.3. Market size and forecast, by Application
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Route of Administration
6.2.4.2.3. Market size and forecast, by Application
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Route of Administration
6.2.4.3.3. Market size and forecast, by Application
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Route of Administration
6.3.3. Market size and forecast, by Application
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Route of Administration
6.3.4.1.3. Market size and forecast, by Application
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Route of Administration
6.3.4.2.3. Market size and forecast, by Application
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Route of Administration
6.3.4.3.3. Market size and forecast, by Application
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Route of Administration
6.3.4.4.3. Market size and forecast, by Application
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Route of Administration
6.3.4.5.3. Market size and forecast, by Application
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Route of Administration
6.3.4.6.3. Market size and forecast, by Application
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Route of Administration
6.4.3. Market size and forecast, by Application
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Route of Administration
6.4.4.1.3. Market size and forecast, by Application
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Route of Administration
6.4.4.2.3. Market size and forecast, by Application
6.4.4.3. India
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Route of Administration
6.4.4.3.3. Market size and forecast, by Application
6.4.4.4. Australia
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Route of Administration
6.4.4.4.3. Market size and forecast, by Application
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Route of Administration
6.4.4.5.3. Market size and forecast, by Application
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Route of Administration
6.4.4.6.3. Market size and forecast, by Application
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Route of Administration
6.5.3. Market size and forecast, by Application
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Route of Administration
6.5.4.1.3. Market size and forecast, by Application
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Route of Administration
6.5.4.2.3. Market size and forecast, by Application
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Route of Administration
6.5.4.3.3. Market size and forecast, by Application
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Route of Administration
6.5.4.4.3. Market size and forecast, by Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. F. Hoffmann-La Roche Ltd.
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. GlaxoSmithKline plc
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Johnson & Johnson
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Merck & Co., Inc.
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Novartis AG
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Pfizer Inc.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Sanofi S.A.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. Bayer AG
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Cipla Ltd
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Amgen Inc.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 02. PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 03. PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 04. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 05. PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 06. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2022-2032 ($BILLION)
TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2022-2032 ($BILLION)
TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($BILLION)
TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($BILLION)
TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 14. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 15. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 16. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 17. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 18. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 19. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 20. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 23. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 24. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 26. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 27. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 28. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 29. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 30. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 31. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 32. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 33. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 34. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 35. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 36. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 37. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 38. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 39. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 40. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 41. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 42. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 43. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 44. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 45. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 46. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 47. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 48. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 49. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 50. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 51. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 52. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 53. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 54. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 55. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 56. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 57. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 58. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 59. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 60. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 61. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 62. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 63. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 64. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 65. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 66. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 67. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 68. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 69. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 70. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 71. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 72. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 73. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 74. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 75. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 76. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 77. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 78. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 79. NOVARTIS AG: KEY EXECUTIVES
TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 83. NOVARTIS AG: KEY STRATERGIES
TABLE 84. PFIZER INC.: KEY EXECUTIVES
TABLE 85. PFIZER INC.: COMPANY SNAPSHOT
TABLE 86. PFIZER INC.: PRODUCT SEGMENTS
TABLE 87. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 88. SANOFI S.A.: KEY EXECUTIVES
TABLE 89. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 90. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 91. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 92. BAYER AG: KEY EXECUTIVES
TABLE 93. BAYER AG: COMPANY SNAPSHOT
TABLE 94. BAYER AG: PRODUCT SEGMENTS
TABLE 95. BAYER AG: PRODUCT PORTFOLIO
TABLE 96. CIPLA LTD: KEY EXECUTIVES
TABLE 97. CIPLA LTD: COMPANY SNAPSHOT
TABLE 98. CIPLA LTD: PRODUCT SEGMENTS
TABLE 99. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 100. AMGEN INC.: KEY EXECUTIVES
TABLE 101. AMGEN INC.: COMPANY SNAPSHOT
TABLE 102. AMGEN INC.: PRODUCT SEGMENTS
TABLE 103. AMGEN INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN PHARMACEUTICAL DRUG DELIVERY MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 10. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. PHARMACEUTICAL DRUG DELIVERY MARKET BY REGION, 2022
FIGURE 22. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 23. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 24. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 28. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 29. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 30. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 31. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 32. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 33. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 34. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 35. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 36. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 37. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 38. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 39. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 40. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 66. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 72. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security